These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 6930206)

  • 21. Anti-hypertensive action of labetalol: a detailed profile.
    Bellamy GR; Hunyor SN; Roffe D; Massang J
    Aust N Z J Med; 1982 Oct; 12(5):467-72. PubMed ID: 6758743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Labetalol in the treatment of hypertension in patients with normal and impaired renal function.
    Walstad RA; Berg KJ; Wessel-Aas T; Nilsen OG
    Acta Med Scand Suppl; 1982; 665():135-41. PubMed ID: 6961760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experience with labetalol in hypertension.
    Bolli P; Waal-Manning J; Wood AJ; Simpson FO
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):765-71. PubMed ID: 791330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Labetalol: an alpha- and beta-blocker.
    Conner CS
    Drug Intell Clin Pharm; 1983; 17(7-8):543-4. PubMed ID: 6135593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
    Prichard BN
    Drugs; 1984; 28 Suppl 2():51-68. PubMed ID: 6151891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Labetalol (AH5158), a competitive alpha- and beta-receptor blocking drug, in the management of hypertension.
    Rosei EA; Brown JJ; Fraser R; Lever AF; Morton JJ; Robertson JI; Trust PM
    Aust N Z J Med; 1976 Aug; 6(3 Suppl):83-8. PubMed ID: 14627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Magnitude and mechanisms of the antihypertensive action of labetalol, including ambulatory assessment.
    Bellamy GR; Hunyor SN; Roffe D; Massang J
    Br J Clin Pharmacol; 1983 Jul; 16(1):9-16. PubMed ID: 6882628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alpha-adrenoceptor blockade by labetalol during long-term dosing.
    Semplicini A; Pessina AC; Rossi GP; Hlede M; Morandin F
    Clin Pharmacol Ther; 1983 Mar; 33(3):278-82. PubMed ID: 6130864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension.
    Wong GW; Laugerotte A; Wright JM
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD007449. PubMed ID: 26306578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Postmarketing comparison of labetalol and propranolol in hypertensive patients.
    Due DL; Giguere GC; Plachetka JR
    Clin Ther; 1986; 8(6):624-31. PubMed ID: 3791361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.
    Lund-Johansen P
    Drugs; 1984; 28 Suppl 2():35-50. PubMed ID: 6151890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A double-blind crossover clinical trial of labetalol and propranolol in patients of essential hypertension.
    Pandhi P; Aslam S; Sharma BK; Sharma PL; Wahi PL
    Int J Clin Pharmacol Ther Toxicol; 1985 Feb; 23(2):101-4. PubMed ID: 3886563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Some haemodynamic effects of compound AH 5158 compared with propranolol, propranolol plus hydrallazine, and diazoxide: the use of AH 5158 in the treatment of hypertension.
    Prichard BN; Thompson FO; Boakes AJ; Joekes AM
    Clin Sci Mol Med Suppl; 1975 Jun; 2():97s-100s. PubMed ID: 802650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparative effects of an alpha 1 and beta 1-2 blocker (labetalol) and a beta-1 blocker (atenolol) in the hypertensive patient].
    Sassard J; Zech PY; Pozet N; Cuisinaud G; Vincent M
    J Pharmacol; 1983; 14 Suppl 2():121-9. PubMed ID: 6355664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Labetalol compared with prindolol plus hydraliazine in the treatment of hypertension: a double-blind cross-over study.
    Barnett AJ; Kalowski S; Guest C
    Med J Aust; 1978 Jan; 1(2):105-9. PubMed ID: 349319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiclinic comparison of labetalol to metoprolol in treatment of mild to moderate systemic hypertension.
    Frishman WH; Michelson EL; Johnson BF; Poland MP
    Am J Med; 1983 Oct; 75(4A):54-67. PubMed ID: 6356900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Labetalol, an alpha- and beta-adrenergic blocking drug in the treatment of hypertension.
    Rosei EA; Fraser R; Morton JJ; Brown JJ; Lever AF; Robertson JI; Trust PM
    Am Heart J; 1977 Jan; 93(1):124-5. PubMed ID: 12654
    [No Abstract]   [Full Text] [Related]  

  • 38. Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension.
    Michelson EL; Frishman WH; Lewis JE; Edwards WT; Flanigan WJ; Bloomfield SS; Johnson BF; Lucas C; Freis ED; Finnerty FA
    Am J Med; 1983 Oct; 75(4A):68-80. PubMed ID: 6356901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Labetalol in general practice: a review.
    Kane JA
    Br J Clin Pharmacol; 1982 Jun; 13(1 Suppl):59S-63S. PubMed ID: 7093101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Labetalol compared with propranolol in patients with both angina pectoris and systemic hypertension: a double-blind study.
    Frishman WH; Shapiro W; Charlap S
    J Clin Pharmacol; 1989 Jun; 29(6):504-11. PubMed ID: 2666451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.